Article Information
History
- August 22, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- J. M. McGree1,*,
- C. Hockham2,3,
- S. Kotwal2,4,
- A. Wilcox2,5,
- A. Bassi6,
- C. Pollock7,8,
- L. M. Burrell9,
- T. Snelling10,11,
- V. Jha2,6,
- M. Jardine2,5,12,
- M. Jones10,
- for the CLARITY Trial Steering Committee
- 1School of Mathematical Sciences, Queensland University of Technology, Brisbane, Australia
- 2The George Institute for Global Health, University of New South Wales, Sydney, Australia
- 3The George Institute for Global Health, Imperial College London, London, UK
- 4Prince of Wales Hospital, Sydney, Australia
- 5NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia
- 6The George Institute for Global Health, New Delhi, India
- 7Royal North Shore Hospital, Sydney, Australia
- 8Kolling Institute of Medical Research, The University of Sydney, Sydney, Australia
- 9Department of Medicine, The University of Melbourne, Austin Health, Victoria, Australia
- 10Sydney School of Public Health, The University of Sydney, Sydney, Australia
- 11The Sydney Children’s Hospitals Network, Westmead, Australia
- 12Concord Repatriation General Hospital, Sydney, Australia
- ↵*Corresponding author (email: james.mcgree{at}qut.edu.au)
Posted August 22, 2021.
Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): Statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial
